The HA-1A saga: the scientific and ethical dilemma of innovative and costly therapies.
Brun-Buisson
C
C
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002986:Clinical Trials as Topic; D017277:Drug Approval; D004731:Endotoxins / Q000276:immunology*; D004992:Ethics, Medical; D005060:Europe; D006801:Humans; D007075:Immunoglobulin M / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D014481:United States
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004731:Endotoxins; D007075:Immunoglobulin M; C068069:nebacumab